Suche
Mein Konto
Frankfurt-Marburg: Millions secured for the future of cancer research!
The Mildred Scheel Young Scientist Center in Frankfurt-Marburg will receive 3.2 million euros for cancer research in order to support young scientists.
Frankfurt-Marburg: Millions secured for the future of cancer research!
From January 1, 2026, the Mildred Scheel Young Talent Center (MSNZ) Frankfurt-Marburg will be funded with 3.2 million euros from the German Cancer Aid Foundation and 800,000 euros from the medical faculties in Frankfurt and Marburg's own funds. These financial resources will be provided over a period of two years and build on the “Mildred Scheel Young Talent Centers” program that has existed since 2018. The aim of the program is to create sustainable training structures and establish long-term career paths for scientists in cancer research in Germany uni-marburg.de reported.
Since its launch, the MSNZ has already supported numerous young scientists in translational cancer research. 62 clinician scientists and medical scientists who are actively involved in cancer research were able to receive funding. This funding is particularly important because it not only offers financial support, but also includes protected research time and measures to balance family and work.
Support and networking
Further funding of the MSNZ will consolidate the existing structures and intensify interdisciplinary exchange. The evaluation of the first funding period is also on the agenda. The medical faculties in Frankfurt and Marburg make a substantial contribution to funding to ensure the high quality of training in cancer research uct-frankfurt.de highlights.
The MSNZ is part of a national network of five Mildred Scheel young talent centers in Germany. Within this network, best practice models for promoting young talent are developed, which include structured support instruments and a tailor-made curriculum. A central element is supporting young scientists in being able to combine career and family.
Research and perspectives
The funding of clinician scientists and medical scientists is part of a comprehensive excellence program that aims to build a new generation of cancer researchers. The recently founded Frankfurt Cancer Institute (FCI) plays a central role in this. It creates optimal framework conditions that enable access to research infrastructures and key technologies for scientific work, such as klinik-nordwest.de supplemented.
Another focus of research at the IKF (Institute for Clinical Oncological Research) includes phase I and proof of concept studies as well as phase III studies. The IKF supports academically initiated clinical research and coordinates a network of over 500 clinical centers in Germany. This commitment contributes to the promotion and development of clinical cancer research.
In summary, the Mildred Scheel Young Research Center initiative shows that Germany is creating supportive structures for young researchers that promise excellent long-term prospects in cancer research.